Novartis recently shared a Winter 2026 update highlighting the FDA approval of ITVISMA® (onasemnogene abeparvovec-brve) for intrathecal use in people ages 2 and older with SMA, offering a one-time gene replacement therapy option. The update also includes ongoing engagement opportunities with the SMA community, upcoming ITVISMA webinars, Adaptive Sports and Recreation resources from Cure SMA, news from SMAshing My Limits, and ways to share your SMA experience with Novartis. They will continue to provide timely updates as they become available.
"Novartis is grateful to the SMA community and its partners for their ongoing engagement, insights, and participation in clinical trials."